Item 7.01 Regulation FD Disclosure.

On August 30, 2021, an article reporting the results of the treatment of a single COVID-19 Long Hauler patient with the Company's lead product, Zofin™, was published online in ScienceDirect's website journal, Respiratory Medicine Case Reports. The article, titled "Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic," was authored by Dr. Maria Ines Mitrani, our Chief Science Officer, Dr. Allen Meglin, one of our directors, Dr. George Shapiro, our Chief Medical Officer and certain other employees of and consultants to Organicell. ScienceDirect is operated by British-Dutch publisher Elsevier Ltd.

The recently published article can be read in full at:

https://www.sciencedirect.com/science/article/pii/S2213007121001647?via%3Dihub

In addition, a copy of the article is included as Exhibit 99.1 to this report.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.   Description

99.1*         Article titled "Treatment of a COVID-19 long hauler with an amniotic
              fluid-derived extracellular vesicle biologic"






*Furnished but not filed.



                                       1

© Edgar Online, source Glimpses